Global clinical trials activity increased by 10.1% in Q2 2021, when compared with the same quarter in 2020, according to GlobalData.
Industry sponsored trials accounted for a 52.3% share of overall activity in Q2 2021, an increase of 7.8% when compared with Q2 2020.
Non-industry sponsored trials accounted for a 47.7% share of all clinical trials in Q2 2021, marking a decrease of 7.8% when compared with the same period in 2020.
Q2 2021 industry sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry sponsored clinical trials in Q2 2021, accounting for a 31.0% share of all trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
This was followed by Infectious Disease with a 17.5% share, Central Nervous System with 12.9%, Cardiovascular with 7.3% and Metabolic Disorders with 6.9%.
In Q2 2020, Infectious Disease led with a 27.7% share, followed by Oncology with 24.8%, Central Nervous System with 11.8%, Respiratory with 8.8%, and Metabolic Disorders with 8.0%.
|Industry sponsored trials: Q2 2021 vs Q2 2020|
|Therapy Area||Q2 2020||Q2 2021||Activity|
|Central Nervous System||11.8%||12.9%|
|Genito Urinary System And Sex Hormones||2.7%||2.4%|
|Ear Nose Throat Disorders||1.6%||0.8%|
|Mouth and Dental Disorders||0.5%||0.6%|
|Non Malignant Disorders||0.2%||0.1%|
Most active therapy areas in non-industry sponsored clinical trials
In Q2 2021 the leading therapy area for non-industry sponsored clinical trials was Oncology, accounting for a 27.0% share of all trials.
This was followed Central Nervous System with a 24.2% share, Infectious Disease with 17.6%, Cardiovascular with 9.8%, and Metabolic Disorders with 5.7%.
In Q2 2020, Infectious Disease held the lead in non-industry sponsored clinical trials with a 35.0% share, followed by Oncology with 19.6%, Central Nervous System with 16.0%, Respiratory with 8.4%, and Cardiovascular with 7.3%.
|Non-Industry sponsored trials: Q2 2021 vs Q2 2020|
|Therapy Area||Q2 2020||Q2 2021||Activity|
|Central Nervous System||16.0%||24.2%|
|Genito Urinary System And Sex Hormones||2.3%||2.6%|
|Mouth and Dental Disorders||1.7%||1.6%|
|Ear Nose Throat Disorders||1.2%||0.7%|
|Non Malignant Disorders||0.4%||0.3%|
Asia-Pacific region has the most activity for industry sponsored clinical trials
Asia-Pacific was the most active region for industry sponsored clinical trials activity in Q2 2021 with a 47.5% share, compared with 57.4% in Q2 2020.
North America was the second most active region with a 37.7% share in Q2 2021, up from 26.6% in Q2 2020, followed by Europe with a 29.9% share in Q2 2021, up from 25.1% in Q2 2020.
Single country studies held an 82.2% share in industry sponsored clinical trials in Q2 2021, compared with 87.2% in Q2 2020. Multinational trials accounted for 17.8% in Q2 2021, against 12.8% in Q2 2020.
Regional activity for non-industry sponsored clinical trials
Asia-Pacific saw the most non-industry sponsored clinical trial activity in Q2 2021 with a 46.8% share, up from 44.5% in Q2 2020.
North America held the second position with a 23.7% share in Q2 2021, compared with 13.5% in Q2 2020. This was followed by Europe with a 19.2% share in Q2 2021, as against 16.4% in Q2 2020.
Single country studies accounted for 98.7% share of non-industry sponsored clinical trials in Q2 2021, compared with 98.8% in Q2 2020. Multinational trials accounted for a 1.3% share in Q2 2021, up from 1.2% in Q2 2020.
Clinical trials by phase in Q2 2021
Phase II trials outnumbered all other studies with a 41.4% share for industry sponsored trials in Q2 2021, compared with 33.8% in Q2 2020.
The share of Phase I trials stood at 28.2% in Q2 2021, down from 37.6% in Q2 2020. Phase III trials increased to 18.3% in Q2 2021, compared with 17.8% in Q2 2020, followed by Phase IV trials with a 12.1% share in Q2 2021, against 10.8% in Q2 2020.
For non-industry sponsored clinical trials, Phase II activity decreased to a 47.9% share in Q2 2021, compared with 41.0% in Q2 2020.
Phase IV trials were the second most active with a 21.3% share in Q2 2021, compared with 18.4% in Q2 2020. Phase III trials held a 16.5% share in Q2 2021, against 26.2% in Q2 2020, followed by Phase I trials with a 14.3% share in Q2 2021, over 14.3% in Q2 2020.
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.